⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632464 | 1.00 | — | — | |
| SCHEMBL11569257 | 0.84 | — | — | |
| SCHEMBL11345386 | 0.81 | — | — | |
| Phosphonic Acid SCHEMBL11341396 | 0.81 | — | — | |
| Hypophosphorous Acid SCHEMBL11345266 | 0.81 | — | — | |
| SCHEMBL11334813 | 0.78 | — | — | |
| SCHEMBL11337938 | 0.74 | — | — | |
| SCHEMBL11587235 | 0.73 | — | — | |
| SCHEMBL894460 | 0.65 | — | — | |
| SCHEMBL12140346 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025059081-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024238404-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20230387548-A1 | Heat/Flame-Resistant Polymer Composite-Based Solid Electrolyte Separator, Lithium Secondary Battery, and Manufacturing Method | GLOBAL GRAPHENE GROUP, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023134374-A1 | PYRIMIDO-HETEROCYCLIC COMPOUND, PREPARATION METHOD, AND USE | 如东凌达生物医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023001069-A1 | MACROCYCLIC AMIDE COMPOUNDS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1515724-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20090253888-A1 | Solid state polymerization process for polyester with phosphinic acid compounds | CIBA CORPORATION | 2009-10-08 | — | — | US | disclosed |
| EP-1635641-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7427637-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7307085-B2 | Kinesin spindle protein (KSP) inhibitors; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator; e.g. bicyclic dihydropyrrole derivatives | MERCK & CO., INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20060024587-A1 | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2006-02-02 | — | — | US | disclosed |